Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Patients Undergoing High Risk PCI. Clear all
Completed Not applicable Interventional

Magenta Elevate™ EFS in High-Risk PCI Patients

NCT05727059
View directory record Official record
Conditions
High-risk Percutaneous Coronary Intervention
Interventions
The Elevate™ System
Device
Lead sponsor
Magenta Medical Ltd.
Industry
Eligibility
18 Years to 84 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Jul 23, 2026, 5:54 PM EDT
Recruiting No phase listed Observational

A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction

NCT05332262
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Assessment of platelet reactivity, Troponin measurement
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 23, 2026, 5:54 PM EDT
Completed Not applicable Interventional Results available

XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

NCT03218787
View directory record Official record
Conditions
Coronary Artery Lesions
Interventions
XIENCE, DAPT
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
101
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Jul 23, 2026, 5:54 PM EDT
Enrolling by invitation Not applicable Interventional

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

NCT05334784
View directory record Official record
Conditions
High-Risk Percutaneous Coronary Intervention
Interventions
Impella ECP
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 23, 2026, 5:54 PM EDT
Active, not recruiting Not applicable Interventional

Impella ECP Early Feasibility Study

NCT04477603
View directory record Official record
Conditions
High-risk Percutaneous Coronary Intervention
Interventions
Impella ECP
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • Paramus, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 23, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Jul 23, 2026, 5:54 PM EDT
Terminated Phase 3 Interventional

Protect II, A Prospective, Multicenter Randomized Controlled Trial

NCT00562016
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
IMPLELLA LP 2.5, IABP Intra-aortic balloon pump
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2011 · Synced Jul 23, 2026, 5:54 PM EDT
Terminated Phase 2 Interventional Results available

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

NCT00910299
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Clearwater, Florida • Jacksonville, Florida • Rome, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Jul 23, 2026, 5:54 PM EDT
Completed Not applicable Interventional

Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

NCT06087575
View directory record Official record
Conditions
Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
Interventions
Supira System
Device
Lead sponsor
Supira Medical
Industry
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Sacramento, California • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 23, 2026, 5:54 PM EDT
Recruiting Not applicable Interventional

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

NCT07296744
View directory record Official record
Conditions
Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Interventions
The Supira System, Impella
Device
Lead sponsor
Supira Medical
Industry
Eligibility
18 Years to 90 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
19
States / cities
Loma Linda, California • Sacramento, California • Thousand Oaks, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI

NCT00534859
View directory record Official record
Conditions
Patients Undergoing High Risk PCI.
Interventions
High Risk PCI
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2011 · Synced Jul 23, 2026, 5:54 PM EDT
Terminated Not applicable Interventional Results available

SHIELD II Clinical Investigation

NCT02468778
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
HeartMate PHP, Any Abiomed Impella® device approved for use in high-risk PCI
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
58
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Jul 23, 2026, 5:54 PM EDT
Recruiting Phase 4 Interventional

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

NCT07025148
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 23, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

NCT01522417
View directory record Official record
Conditions
Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
Interventions
Short Tirofiban, Eptifibatide, Long Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
13
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 23, 2026, 5:54 PM EDT